Published in Antimicrob Agents Chemother on April 01, 1984
Overview of medically important antifungal azole derivatives. Clin Microbiol Rev (1988) 3.33
Broth dilution testing of Candida albicans susceptibility to ketoconazole. Antimicrob Agents Chemother (1987) 1.57
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother (1995) 1.35
Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother (1991) 1.23
In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother (1992) 1.09
Activity of compound G2 isolated from alfalfa roots against medically important yeasts. Antimicrob Agents Chemother (1986) 1.05
In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother (1994) 0.80
Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis. Antimicrob Agents Chemother (1986) 0.79
Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and Candida parapsilosis. Antimicrob Agents Chemother (1984) 0.76
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis (1972) 7.47
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs (1982) 3.34
Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother (1983) 3.06
Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J Infect Dis (1978) 2.51
The action of miconazole of the growth of Candida albicans. Sabouraudia (1975) 2.32
Clotrimazole: new drug for systemic mycoses? Ann Intern Med (1970) 1.99
Heterogeneity of action of mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother (1981) 1.94
Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother (1979) 1.75
Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs (1980) 1.43
Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother (1972) 1.28
Antagonistic action of lipid components of membranes from Candida albicans and various other lipids on two imidazole antimycotics, clotrimazole and miconazole. Antimicrob Agents Chemother (1977) 1.10
Preliminary studies on the pharmacology and therapeutic activity of oral and intravenous econazole. Mykosen Suppl (1978) 1.04
Persistence of miconazole in vaginal secretions after single applications. Implications for the treatment of vaginal candidosis. Br J Vener Dis (1981) 0.82
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
A Candida albicans dispersed, repeated gene family and its epidemiologic applications. Proc Natl Acad Sci U S A (1988) 7.75
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Direct allelic variation scanning of the yeast genome. Science (1998) 5.90
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis (1978) 3.75
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis (1975) 2.99
Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother (1979) 2.84
Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis (1990) 2.66
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics (1994) 2.41
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis (1992) 2.41
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med (1982) 2.25
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother (1992) 2.22
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol (1999) 2.15
Treatment of mycoses with itraconazole. Ann N Y Acad Sci (1988) 2.11
Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother (1997) 2.07
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Ketoconazole blocks testosterone synthesis. Arch Intern Med (1982) 2.01
Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest (1991) 2.00
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Distribution of a corticosteroid-binding protein in Candida and other fungal genera. J Gen Microbiol (1983) 1.86
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother (1988) 1.85
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother (1990) 1.81
Postexposure varicella management of nonimmune personnel: an alternative approach. Infect Control Hosp Epidemiol (1994) 1.77
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med (1989) 1.76
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
A five-year study of needlestick injuries: significant reduction associated with communication, education, and convenient placement of sharps containers. Infect Control Hosp Epidemiol (1992) 1.72
Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother (1991) 1.72
Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae. Infect Immun (1994) 1.72
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J Infect Dis (1994) 1.69
Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun (1984) 1.65
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
Pathogen factors and host factors in murine pulmonary blastomycosis. Mycopathologia (1982) 1.61
Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (1991) 1.61
Emerging pathogens. Med Mycol (2000) 1.59
Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med (1991) 1.58
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med (2000) 1.58
Treatment of fungal meningitis with miconazole. Arch Intern Med (1977) 1.57
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens. Antimicrob Agents Chemother (1989) 1.53
Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America. Clin Infect Dis (2000) 1.53
Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole. Rev Infect Dis (1987) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis. J Med Vet Mycol (1994) 1.52
Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother (1992) 1.52
Spontaneous mutant of Blastomyces dermatitidis attenuated in virulence for mice. Sabouraudia (1982) 1.51
High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med (1984) 1.51
Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother (1992) 1.50
Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother (1991) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. Proc Natl Acad Sci U S A (1983) 1.47
Standardized management of patients and employees exposed to pertussis. Infect Control Hosp Epidemiol (1998) 1.46
Epidemiologic study by DNA typing of a Candida albicans outbreak in heroin addicts. J Clin Microbiol (1991) 1.44
Itraconazole treatment of coccidioidomycosis. NAIAD Mycoses Study Group. Am J Med (1990) 1.43
Comparative analysis of genetic variability among Candida albicans isolates from different geographic locales by three genotypic methods. J Clin Microbiol (1997) 1.42
Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother (1994) 1.41
Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med (1997) 1.41
Standardization and certification of reference antigens and antisera for 30 human adenovirus serotypes. Am J Epidemiol (1967) 1.41
Laboratory evaluation of an outbreak of nocardiosis in immunocompromised hosts. Am J Med (1981) 1.40
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis (1991) 1.40
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
Susceptibility differences of inbred strains of mice to blastomycosis. Infect Immun (1981) 1.37
Comparison of various techniques for determining viability of Paracoccidioides brasiliensis yeast-form cells. J Clin Microbiol (1982) 1.35
Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother (1987) 1.34
Dermal sensitivity to different doses of spherulin and coccidioidin. Chest (1974) 1.33
Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother (1992) 1.33
In vivo and in vitro activation of pulmonary macrophages by IFN-gamma for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J Immunol (1988) 1.32
Deep infections from Petriellidium boydii treated with miconazole. JAMA (1979) 1.32
Macrophages and fungi: in vitro effects of method of macrophage induction, activation by different stimuli, and soluble factors on Blastomyces. J Reticuloendothel Soc (1980) 1.31
Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol (1998) 1.30
Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med (1995) 1.29
Antifungal drug susceptibility testing. A critical review. Mycopathologia (1984) 1.27
Complement fixation antibody test for human nocardiosis. J Clin Microbiol (1978) 1.27
Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother (1998) 1.26
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med (1983) 1.26
Intracellular multiplication of Paracoccidioides brasiliensis in macrophages: killing and restriction of multiplication by activated macrophages. Infect Immun (1989) 1.25
Virulence of fungi: correlation of virulence of Blastomyces dermatitidis in vivo with escape from macrophage inhibition of replication in vitro. Infect Immun (1981) 1.25
Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob Agents Chemother (1991) 1.23